Index

ability to work 396
Activities of Daily Living (ADL), survivorship studies 249
Acute Radiation Morbidity Scoring Criteria 206
adjuvant therapy, breast cancer 93, 95
cost-effectiveness study 507–8
HRQOL studies 106–7, 109
long-term late effects 115
administrative data 526–8
enhancements to support outcomes research 529
strengths and limitations 528–9
Affect Balance Scale (ABS) 249
Agency for Healthcare Research and Quality (AHRQ)
Healthcare Cost and Utilization Project (HCUP) 534, 537
Integrated Delivery System Research Network (IDSRN) 543
Medical Expenditure Panel Survey (MEPS) 534, 537
Primary Care Practice-Based Research Networks (PBRNs) 543
ggregated scores 392, 465
derivation for multidimensional instruments 476–7, 577
item aggregation 476
subscale aggregation 476–7
see also summary scales and scores
allowed amounts 488–9
ambulatory care costing algorithms 490
American Cancer Society, Study of Cancer Survivors-II (SDS-II), 532, 536
American Society of Clinical Oncology (ASCO), National Initiative on Cancer Care Quality (NICCQ) 540–1
analytical techniques 10
see also statistical analyses in outcomes research
androgen deprivation 127–8, 203
see also hormonal therapy
anemia 625–30
Appraisal of Caregiving Scale (ACS) 338, 339
Area Resource File (ARF) 537
area under curve (AUC) statistic 374
<table>
<thead>
<tr>
<th>Assessment of Patients’ Experience of Cancer Care (APECC) Study</th>
<th>533, 536</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asset and Health Dynamics (AHEAD) Study</td>
<td>493, 535, 538</td>
</tr>
<tr>
<td>audio-CASI (computer-assisted self-interview)</td>
<td>352</td>
</tr>
<tr>
<td>balance billing</td>
<td>489</td>
</tr>
<tr>
<td>balance of error</td>
<td>474</td>
</tr>
<tr>
<td>Bayesian methodology</td>
<td>379–80, 515, 561, 577–8, 632–3</td>
</tr>
<tr>
<td>in cost-effectiveness analysis</td>
<td>515–16</td>
</tr>
<tr>
<td>in patient-reported outcome analysis</td>
<td>632–3</td>
</tr>
<tr>
<td>Behavioral Risk Factor Surveillance System</td>
<td>530, 531</td>
</tr>
<tr>
<td>billed charges</td>
<td>488</td>
</tr>
<tr>
<td>bisphosphonates, symptom control in breast cancer</td>
<td>110</td>
</tr>
<tr>
<td>blood pressure measurement</td>
<td>2</td>
</tr>
<tr>
<td>bowel symptoms</td>
<td>131, 150</td>
</tr>
<tr>
<td>survivorship studies</td>
<td>245</td>
</tr>
<tr>
<td>see also colorectal cancer</td>
<td></td>
</tr>
<tr>
<td>BRCA1/BRCA2 genes</td>
<td>222–4</td>
</tr>
<tr>
<td>breast cancer</td>
<td>5</td>
</tr>
<tr>
<td>chemoprevention 220–1</td>
<td></td>
</tr>
<tr>
<td>short-term outcome measurement</td>
<td>219</td>
</tr>
<tr>
<td>economic burden</td>
<td>485</td>
</tr>
<tr>
<td>epidemiology</td>
<td>93</td>
</tr>
<tr>
<td>genetic testing</td>
<td>222–4</td>
</tr>
<tr>
<td>short-term outcome measurement</td>
<td>223</td>
</tr>
<tr>
<td>HRQOL studies</td>
<td>9, 94, 107–8, 578</td>
</tr>
<tr>
<td>added benefits of</td>
<td>111–13</td>
</tr>
<tr>
<td>adjuvant drug therapy</td>
<td>106–7, 109, 115</td>
</tr>
<tr>
<td>advanced disease treatment</td>
<td>107–8, 109–10</td>
</tr>
<tr>
<td>follow-up studies</td>
<td>108, 110</td>
</tr>
<tr>
<td>future research needs</td>
<td>113–16</td>
</tr>
<tr>
<td>history of</td>
<td>94–5</td>
</tr>
<tr>
<td>in clinical trials</td>
<td>95, 105–11, 114–15, 116</td>
</tr>
<tr>
<td>instrument selection</td>
<td>104–5</td>
</tr>
<tr>
<td>instruments used</td>
<td>96–7, 101, 105–6</td>
</tr>
<tr>
<td>literature review</td>
<td>96</td>
</tr>
<tr>
<td>primary breast tumor treatment</td>
<td>106, 107</td>
</tr>
<tr>
<td>psychosocial interventions</td>
<td>108, 110–11, 115</td>
</tr>
<tr>
<td>recommendations</td>
<td>113–16</td>
</tr>
<tr>
<td>studies using more than one instrument</td>
<td>101–5</td>
</tr>
<tr>
<td>symptom control</td>
<td>108, 110</td>
</tr>
<tr>
<td>prognosis</td>
<td>93–4</td>
</tr>
<tr>
<td>outcome prediction</td>
<td>112</td>
</tr>
<tr>
<td>psychological impacts</td>
<td>94–5, 115</td>
</tr>
<tr>
<td>screening</td>
<td>228–9</td>
</tr>
<tr>
<td>false positive screening results</td>
<td>228–9</td>
</tr>
<tr>
<td>negative screening results</td>
<td>228</td>
</tr>
<tr>
<td>short-term outcomes measurement</td>
<td>225–7</td>
</tr>
<tr>
<td>instruments used</td>
<td>245–53</td>
</tr>
<tr>
<td>treatments</td>
<td>93, 202–3</td>
</tr>
<tr>
<td>adjuvant drug therapy</td>
<td>93, 95, 106–9, 115</td>
</tr>
<tr>
<td>advanced disease</td>
<td>109–10</td>
</tr>
<tr>
<td>cost-effectiveness analysis</td>
<td>507–8</td>
</tr>
<tr>
<td>cost-utility analysis</td>
<td>505</td>
</tr>
<tr>
<td>impact on patients</td>
<td>204–5, 210</td>
</tr>
<tr>
<td>primary breast tumor</td>
<td>106</td>
</tr>
<tr>
<td>treatment decisions</td>
<td>93, 106–10, 112, 115–16</td>
</tr>
<tr>
<td>see also cancer treatments</td>
<td></td>
</tr>
<tr>
<td>Breast Cancer Chemotherapy Questionnaire (BCQ)</td>
<td>95, 101, 105</td>
</tr>
<tr>
<td>Breast Cancer Prevention Trial (BCPT)</td>
<td>219, 220</td>
</tr>
<tr>
<td>Breast Cancer Surveillance Consortium</td>
<td>541</td>
</tr>
<tr>
<td>Brief Hospice Inventory (BHI)</td>
<td>267–9, 274, 277</td>
</tr>
<tr>
<td>Brief Male Sexual Function Inventory (BSFI)</td>
<td>126, 146–7</td>
</tr>
<tr>
<td>Brief Symptom Inventory-53 (BSI-53)</td>
<td>247, 252</td>
</tr>
<tr>
<td>burden, concept of</td>
<td>480</td>
</tr>
<tr>
<td>see also economic burden of cancer</td>
<td></td>
</tr>
<tr>
<td>Burden Scale</td>
<td>339</td>
</tr>
<tr>
<td>California Health Interview Survey (CHIS)</td>
<td>530, 531</td>
</tr>
<tr>
<td>cancer</td>
<td></td>
</tr>
<tr>
<td>disease focus</td>
<td>5</td>
</tr>
<tr>
<td>epidemiology</td>
<td>1</td>
</tr>
<tr>
<td>impact on individual</td>
<td>1, 24</td>
</tr>
<tr>
<td>outcomes</td>
<td>see outcomes research</td>
</tr>
<tr>
<td>see also breast cancer, colorectal cancer, economic burden of cancer, lung cancer, prostate cancer</td>
<td></td>
</tr>
<tr>
<td>cancer care</td>
<td></td>
</tr>
<tr>
<td>continuum of care</td>
<td>5</td>
</tr>
<tr>
<td>HRQOL assessment across</td>
<td>9–10</td>
</tr>
<tr>
<td>patient perspective across</td>
<td>297</td>
</tr>
<tr>
<td>prostate cancer</td>
<td>346</td>
</tr>
<tr>
<td>defining cancer care episodes</td>
<td>486–8</td>
</tr>
<tr>
<td>concurrent episode coding</td>
<td>486–7</td>
</tr>
<tr>
<td>retrospective computerized episode algorithms</td>
<td>488</td>
</tr>
<tr>
<td>retrospective episode coding</td>
<td>487–8</td>
</tr>
<tr>
<td>long-term care costs</td>
<td>491–2</td>
</tr>
<tr>
<td>medical care costs</td>
<td>1, 482–91</td>
</tr>
<tr>
<td>quality of care</td>
<td>3</td>
</tr>
<tr>
<td>categories of</td>
<td>291</td>
</tr>
<tr>
<td>patient perspectives</td>
<td>290–2</td>
</tr>
</tbody>
</table>
Index 641

Cancer Inventory of Problem Situations (CIPS)
96–8

Cancer Rehabilitation Evaluation System (CARES)
15, 45–54, 95

Cancer Outcomes Measurement Working Group (COMWG)
3–4, 568–9

Cancer Outcomes Research and Surveillance Consortium (CanCORS)
538, 540

Cancer Outcomes Research Teams (CORTs)
581

Cancer Patient Need Questionnaire (CPNQ)
310

Cancer Patient Need Survey (CPNS)
309, 310

cancer care

Cancer Inventory of Problem Situations (CIPS)
96–8

se also cancer treatments; caregivers; patient perspectives on cancer care

Cancer Outcomes Measurement Working Group (COMWG)
3–4, 568–9

common approach establishment 7–8

approach to tables 8

categorization of HRQOL measures 7–8

defining HRQOL 7

evaluation of outcome measurement instruments 7

data sources 6–7

development of 4

focus groups 6–7

future directions 580–2

sustaining scientific advancement 580–1

membership 4

operations of 6

outcomes assessment framework 4–6

arenas of application 5

continuum of care 5

disease focus 5

outcome measures of prime interest 4–5

Cancer Outcomes Research and Surveillance Consortium (CanCORS)
538, 540

Cancer Outcomes Research Teams (CORTs)
581

Cancer Patient Need Survey (CPNS)
309, 310

cancer patients

needs of 310, 320–2

se also needs; needs assessment

terminally ill patients see end-of-life (EOL) care

treatment impact on 201–2, 210–13, 550

domains of HRQOL affected 204–5

late effects 115, 244

patient-reported instruments 207

treatment preferences 115–16, 288

direct studies 77–8

proxy assessment of patient preferences 349

see also patient perspectives on cancer care; patient-reported outcomes (PROs)

cancer prevention 216, 217

decision making 217

HRQOL studies 9

prophylactic surgery 224

short-term outcomes 217, 231–2

literature review 218

measurement of 229–31

measures 218

se also chemotherapy

cancer registries 523–6

enhancements to support outcomes research 525–6

strengths and limitations 525

Cancer Rehabilitation Evaluation System (CARES) 15, 45–54

Cancer Research Network (CRN)
541

cancer treatments 1

economic cost of 1

goal of 823

impact on cancer patients 201–2, 210–13, 550

domains of HRQOL affected 204–5

late effects 115, 244

measurement 206–13

patient-reported instruments 207

outcomes see outcomes research

survivor's perspective 287

treatment decisions 201, 389–90

breast cancer 93, 106–10, 112, 115–16

colorectal cancer 193, 194–5

lung cancer 160

prostate cancer 147, 148–50, 558

se also clinical decision making

treatment preferences 115–16, 288

direct studies 77–8

proxy assessment of patient preferences 349

se also cancer care; chemotherapy; drug development; radiation therapy; specific types of cancer; surgical treatment

© Cambridge University Press www.cambridge.org

Cambridge University Press 0521838908 - Outcomes Assessment in Cancer: Measures, Methods, and Applications Edited by Joseph Lipscomb, Carolyn C. Gotay and Claire Snyder

More information
Cancer Worry Scale 249
Caregiver Appraisal Scale 339
Caregiver Quality of Life Index (CQOLC) 334, 335–6, 338, 340–1, 342–3
comparison with Caregiver Reaction Assessment (CRA) 340–1
construct validity 338, 341
reliability 338, 341
responsiveness 338, 339, 341
Caregiver Reaction Assessment (CRA) 334–6, 338, 340–1, 342–3
comparison with Caregiver Quality of Life Index-Cancer (CQOLC) 340–1
construct validity 337, 341
reliability 337, 341
responsiveness 337, 341
subscales 337

caregivers 10, 331
at-risk caregivers 342
impacts on 10, 329–30, 331, 332, 340
analysis 330–1
conceptual model 331–4
data abstraction 330
economic burden 493–4
emotional domain 331–3
end-of-life care 264–5
future research 341–2
literature search 330
objective impacts 329
physical domain 333
positive impacts 333, 341
social/role domain 333
spiritual domain 333–4, 341–2
subjective impacts 329–30, 331, 332
uses of caregiver impact information 342
measures of caregiver impact 334–6, 340, 342–3
overall description 334
needs of 310, 320–2
proxy measures of patient-oriented outcomes 348–9
see also family members and friends
CARES see Cancer Rehabilitation Evaluation System (CARES)
cascading 231
category response curves (CRCs) 431, 448–51
ceiling effects 597
Center for Epidemiologic Studies-Depression (CES-D) survivorship studies 247, 252
cervical cancer
chemoprevention 221–2
short-term outcome measurement 219
screening 228–9
false positive screening results 228–9
negative screening results 228
short-term outcomes measurement 225–7
chaining 231
Charlson Index 151
cervical cancer 219, 221–2
breast cancer 219, 220–1
cervical cancer 219, 221–2
colorectal cancer 219, 221
impact on HRQOL 219–22, 230
prostate cancer 126, 219, 221
short-term outcomes 217, 231–2
literature review 218
measurement of 219, 229–31
measures 218
see also cancer prevention
chemotherapy
breast cancer 202–3
cost-effectiveness analysis 507–8
HRQOL studies 95, 109
symptom control 110
colorectal cancer 178, 203
HRQOL studies 185, 193, 194–5
impact on cancer patients 201–2, 550, 625–30
cognitive impact 630
domains of HRQOL affected 205
HRQOL endpoint data 559
measurement 208–10
patient-reported instruments 207
toxicity criteria 206–7
see also specific types of cancer
lung cancer 203
cost-effectiveness analysis 504
HRQOL studies 166
prostate cancer 128, 203
see also adjuvant therapy; cancer treatments; drug development; hormonal therapy
Chemotherapy Symptom Assessment Scale (C-SAS) 208–9
childhood cancers 346–7
City of Hope (COH) model 17
Quality of Life Scale (QOLS) 273–1, 275, 277
Clarke and Talcotti prostate cancer specific questionnaire 128, 135, 136
psychometric properties 135
classical test theory (CTT) 425, 596–1
comparision to item response theory (IRT) modeling 433–8, 575–8, 591
computerized adaptive testing 439
differential item functioning 439–40, 576
information 436–8
invariance 435–6
optimal scaling/scale score interpretation 440–1
scale development and analysis 438–9
limitations 445, 469, 590
clinical decision making 389–90
cost-effectiveness plane 506–7
in cancer prevention 217
in screening 217
levels of 391
macro level 391
meso level 391
micro level 391
use of HRQOL information 10, 389–90, 554, 558–9, 581
from observational studies and clinical trials 388
instrument selection 378–9
interpretation of HRQOL data 397
see also cancer treatments
clinical response benefit 368, 379
clinical significance 370, 631–2
assessment 379, 560–1
clinical trials 11
breast cancer 95, 105–11, 114–15, 116
design of 587
economic analyses 347
see also cost-effectiveness analysis (CEA)
economic studies for new products 633–6
challenges and timing 634–5
modeling in economic evaluations 635–6
HRQOL instrument selection 578
incorporation of patient-reported outcomes 346–7, 552–3, 624
data collection modes 348–53
decision modeling 633
measurement across phases of drug development 348
measurement across stages of disease 346–4
missing data 353–5, 631
multiple testing 631
recommendations 358–9
regulatory perspective 552–3
timing and administration 355–6
lung cancer 169
prostate cancer 148–50
cognitive aspects of survey methodology (CASM) 610
cognitive interviewing technique 610, 611, 621
detecting and fixing problems with questions 611–12
general versus specific application 612
investigating frame-of-reference effects 618–19
item selection related to respondent interpretation 613–16
how respondents conceive of health 614–15
investigator and respondent characterization of concepts 613–14
selection of response category 615–16
reference periods 616–17
probing the past 617
probing the present 616
responses to sensitive topics 617–18
responses to socially desirable behaviors 617–18
strengths and weaknesses 619–21
logistics 620
potential for bias 619–20
replacement of other evaluation methods 620
use in cross-cultural assessment 621
use in self-administered instruments 620–1
verbal probing versus think-aloud 611
cognitive testing 301
colon cancer 178
treatment 178
see also colorectal cancer
coloscopy 224
cost-effectiveness analysis 512
colorectal cancer (CRC) 5
chemoprevention 221
short-term outcome measurement 219
economic burden of 485
epidemiology 178
HRQOL studies 9, 571
clinical implications 193–5
future research needs 195
instruments used 179–84
literature search 179
measurement issues 184–5
performance of HRQOL measures 192–3
qualitative findings 190–1
recommendations 195
routine outcomes 185–90
value added 191–2
screening 178, 224–8, 536
cost-effectiveness analysis 512
short-term outcome measurement 225–7
survivorship studies 245
instruments used 245–51
© Cambridge University Press www.cambridge.org
colorectal cancer (CRC) (cont.)
treatments 9, 178, 187, 203
impact on patients 185–90, 205
metastatic disease 186–7, 188–90
mixed treatments 185–8
treatment decisions 193, 194–5
see also cancer treatments
Common Toxicity Criteria 206
communication issues
facilitation of communication 390–1
in end-of-life care 280
interaction analysis 291–2
survivor’s perspective 287–8
see also interpersonal care
computer therapy 511–12
Comprehensive Assessment of Satisfaction with Care
Questionnaire (CASC) 293–4
computer use for patient-reported data collection 351–2
digital divide significance 586
hand-held computers 352
computer-assisted preference elicitation 16–7
computer-assisted self-interview (CASE) 352
computer-assisted adaptive testing (CAT) 439, 445–6, 459–61, 576, 582
health status assessment 598
conceptual equivalence 595
concurrent episode coding 486–7
conjoint analysis 322–4
hybrid conjoint model 324, 325
ConQuest program 477
construct map 466–8
Consumer Assessment of Health Plans (CAHPS) survey 292, 285, 289, 300, 530, 532
response options 296
continuum of care 5
HRQOL assessment across 9–10, 570
patient perspective across 287
prostate cancer 126–8
see also cancer prevention; end-of-life (EOL) care; screening
core constructs 579–80
cost management information systems (CMISs) 489
Cost of Cancer Treatment Study 495
cost-benefit analysis (CBA) 585–6
cost-effectiveness analysis (CEA) 70–1, 347–8, 398, 494, 563, 504
Bayesian methods 515–18
decision analytic models 507–11
data incorporation 508
data modeling 508–10
model structure 507–8
model validation 510–11
expected value of information 516
integration of trials and models 516–18
net benefit analysis 514–15
randomized cost-effectiveness trials 511–13
efficacy versus effectiveness endpoints 512
integration of evidence 513
protocol effects 512
truncated follow-up time 512–13
wrong comparator therapy 511–12
sensitivity analysis 513–14
summary score 577
see also economic evaluation
cost-effectiveness plane 506–7
cost-minimization analysis (CMA) 504
cost-utility analysis (CUA) 70, 504–5
costing algorithms 490
costs
assigning costs to specific procedures and services 488–90
allowed amounts 488–9
balance billing 489
costing algorithms 490
list prices/billed charges 488
paid amounts 489
production costs 489–90
revenues 489
drug costs 490
versus prices 588–9
hospitalization costs 485
household costs induced 492–4
long-term care costs induced 491–2
lost productivity costs induced 492–4
measurement of attributable costs 485–8
comparison sample strategy 486
defining cancer care episodes 486–8
microcosting strategy 486
top-down strategy 485–6
medical care costs induced 1, 482–91
societal costs 495–6
counseling or genetic counseling; psychosocial interventions
Crombach’s alpha 316–17
cross-cultural use of HRQOL assessments 406–7
Cancer Rehabilitation Evaluation System (CARES) 408–9, 420
psychometric performance 409
Short Form (CARES-SF) 408–9
EORTC QLQ-C30 411–12, 419, 420–1
psychometric performance 412–13, 416
Functional Assessment of Cancer Therapy-General (FACT-G) 416, 419, 420–1
psychometric performance 416–18

Functional Living Index Cancer (FLIC) 407–8
psychometric performance 407–8

Rotterdam Symptom Checklist (RSCL) 409–10
psychometric performance 410–11

Cultural issues 296, 596
cognitive interviewing 621
disenfranchisement 595–6
see also cross-cultural use of HRQOL assessments

Dale et al. prostate cancer specific questionnaire 128, 135, 136
psychometric properties 135, 136
data collection from patients see patient-reported outcomes (PROs)
data sources 6–7, 11, 522
administrative data 526–8
enhancements to support outcomes research 529
strengths and limitations 528–9
cancer registries 523–6
enhancements to support outcomes research 525–6
strengths and limitations 525
enhancement 581
focus group 523
literature search 522–3
mechanisms 523–6, 539–44
consortia and networks 540–4
industry-supported mechanisms 544
single organizations 539–40
medical records 526, 528
enhancements to support outcomes research 529
strengths and limitations 529
surveys 530–3, 539
enhancements to support outcomes research 530
strengths and limitations 530
research use and cost 534–5, 536–8
strengths and limitations 538
towards a national cancer data system 544–6
decision analytic models 507–11
data incorporation 508
data modeling 508–10
model structure 507–8
model validation 510–11
decision making see clinical decision making
decision modeling 633
decision significance 573
decision trees 507, 508, 509
Department of Defense (DoD), Military Cancer Institute 539
Department of Veterans Affairs (VA) 539
Colonial Breast Cancer Quality Enhancement Research Initiative (CBC QERI) project 539–40
depression
genetic counseling and 222
Hospital Anxiety and Depression Scale (HADS) 32–3
Derdiarian Informational Needs Assessment (DINA) 312
Diagnosis, survivor’s perspective 296–7
Diagnosis Related Groups (DRGs) 490
differential item functioning (DIF) 439–40, 576, 592, 596, 620
alternative language instrument evaluation 412, 419
digital divide 596
dimensionality 592–3
multidimensional approach 11, 438, 465, 576–7
unidimensionality 432–3, 440–4, 465, 592, 593
disability measurement 590
disability-adjusted life years (DALYs) 485, 496–7
disadvantaged populations 585
disenfranchisement 585–6
disaggregated scores 392
discomfort measurement 590
discovery methods 391–2
disenfranchisement 550–6
digital divide 596
distance 469–70
drug costs 490
versus drug prices 588–9
development 624, 636
development phases 551
phase I studies 551
phase II studies 551
phase III studies 551
phase IV studies 551
economic studies for new products 613–6
challenges and timing 614–5
modeling in economic evaluations 615–6
promotional claims 553–4, 555, 556–7, 559–60
patient-reported outcomes and 620–1
regulatory issues 552–4
drug evaluation 588
use of HRQOL data 11–12, 550, 551–4, 555
industry perspective 554–5, 624
patient-reported outcome measures 348
see also clinical trials
drug labeling 552, 553–4, 555, 559–60
patient-reported outcomes and 625–9, 630
drug therapy see chemotherapy
Eastern Cooperative Oncology Group (ECOG) measure 369–70, 386
economic analysis see economic evaluation
economic burden of cancer 1, 11, 480–1, 572
applications 482
challenges 496–9
equity issues 496, 498–9
total societal value-loss 496–8
economic evaluations 482, 490–1, 494
formal long-term care costs induced 491–2
formal medical care costs induced 1, 482–91
household costs induced 492–4
lost productivity costs induced 492–4
methodological approaches 481–2
macrocosting 481, 485–90, 492
microcosting 481, 485, 486, 487, 492
modeling 481–2
patient-level burden 482, 485–90, 493–4
assigning costs to procedures and services 488–90
measuring attributable costs 485–8
population-level burden 482, 492–3
prostate cancer 485
see also cost-effectiveness analysis, costs
economic evaluation 480, 482, 503–7
clinical trials 347
cost-benefit analysis (CBA) 505–6
cost-effectiveness plane 506–7
see also cost-effectiveness analysis
cost-minimization analysis (CMA) 504
cost-utility analysis (CUA) 70, 504–5
household costs 494
lost productivity costs 494
medical care costs 490–1
new oncology products 633–6
challenges and timing 634–5
modeling in economic evaluations 635–6
rational 365–4
Edmonton Symptom Assessment System (ESAS) 269–71, 275, 277
Educational Testing Service (ETS) 601
effectiveness studies 398, 512
emancipation studies 398, 512
end results 1–2
see also end points
end-of-life (EOL) care 23, 284
domains of HRQOL affected 265–6
physical well-being 286
psychological well-being 286
social well-being 286
spiritual well-being 286
HRQOL studies 16, 264, 276
barriers to EOL research 279
in health services research 279
instruments used 17, 266–7, 276
longitudinal designs 278–9
moving away from narrow symptom focus 276–7
positive versus quantitative methods 279
role in palliative care research 278–80
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
deck-of-scale aversion 72
endpoints 1–2, 386
clinical response benefit 368, 379
construction and validation of 379
efficacy versus effectiveness endpoints 512
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 356–7, 370–1
see also health-related quality of life (HRQOL)
cancer continuum 54
lung cancer module (LC-13) 161, 162–4, 171
lung cancer studies 161–2
performance of instrument 192
pertinent measures 276
qualities of instrument 192
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
deck-of-scale aversion 72
endpoints 1–2, 386
clinical response benefit 368, 379
construction and validation of 379
efficacy versus effectiveness endpoints 512
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 356–7, 370–1
see also health-related quality of life (HRQOL)
cancer continuum 54
lung cancer module (LC-13) 161, 162–4, 171
lung cancer studies 161–2
performance of instrument 192
pertinent measures 276
qualities of instrument 192
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
deck-of-scale aversion 72
endpoints 1–2, 386
clinical response benefit 368, 379
construction and validation of 379
efficacy versus effectiveness endpoints 512
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 356–7, 370–1
see also health-related quality of life (HRQOL)
cancer continuum 54
lung cancer module (LC-13) 161, 162–4, 171
lung cancer studies 161–2
performance of instrument 192
pertinent measures 276
qualities of instrument 192
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
deck-of-scale aversion 72
endpoints 1–2, 386
clinical response benefit 368, 379
construction and validation of 379
efficacy versus effectiveness endpoints 512
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 356–7, 370–1
see also health-related quality of life (HRQOL)
cancer continuum 54
lung cancer module (LC-13) 161, 162–4, 171
lung cancer studies 161–2
performance of instrument 192
pertinent measures 276
qualities of instrument 192
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
deck-of-scale aversion 72
endpoints 1–2, 386
clinical response benefit 368, 379
construction and validation of 379
efficacy versus effectiveness endpoints 512
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 356–7, 370–1
see also health-related quality of life (HRQOL)
cancer continuum 54
lung cancer module (LC-13) 161, 162–4, 171
lung cancer studies 161–2
performance of instrument 192
pertinent measures 276
qualities of instrument 192
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
deck-of-scale aversion 72
endpoints 1–2, 386
clinical response benefit 368, 379
construction and validation of 379
efficacy versus effectiveness endpoints 512
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 356–7, 370–1
see also health-related quality of life (HRQOL)
cancer continuum 54
lung cancer module (LC-13) 161, 162–4, 171
lung cancer studies 161–2
performance of instrument 192
pertinent measures 276
qualities of instrument 192
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
deck-of-scale aversion 72
endpoints 1–2, 386
clinical response benefit 368, 379
construction and validation of 379
efficacy versus effectiveness endpoints 512
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 356–7, 370–1
see also health-related quality of life (HRQOL)
cancer continuum 54
lung cancer module (LC-13) 161, 162–4, 171
lung cancer studies 161–2
performance of instrument 192
pertinent measures 276
qualities of instrument 192
subject burden 277–8
impact on caregivers 285
importance of HRQOL 284–5
prostate cancer 128
see also palliative care
prostate cancer studies 120, 145, 148, 151
representative scores 141
psychometric data and validation 46–53, 99–100, 412–13, 414, 415, 416
quality-of-life dimensions 16
Subjective Significance Questionnaire (SSQ) 394–5
survivorship studies 246, 251, 255
translation and cultural adaptation 411–12, 419, 420–1
psychometric performance 412–13, 416
type of information elicited 21
usage 54–5
epoetin alfa 625–30
equity issues
canonical equivalence 595
digital divide 596
disadvantaged populations 595
in economic burden measurement 496, 498–9
psychometric equivalence 595
European Organization for Research and Treatment of Cancer (EORTC)
Core Quality of Life Questionnaire see EORTC QLQ-C30
toxicity criteria 206
European Randomized Study of Screening for Prostate Cancer 127
EuroQol EQ-5D 78–80, 179
colorectal cancer studies 190
components 78–9
measurement properties 79–80
construct validity 79
content validity 79
practical aspects 80
reliability 78–80
responsiveness 80
strengths and limitations 85
evaluations, in subjective assessment 19–23, 27
changes over time 23
in definitions of quality of life 28–2
influencing factors 22–3
measurement of 22
Expanded Prostate Cancer Index Composite (EPIC) 126, 135–7, 146, 152
psychometric properties 135–7
representative scores 144
expectations 297–8
influence on patient evaluations 297–8, 299
expected utility theory 73
expected value of perfect information (EVPPI) 516, 517
expected value of sample information (EVSI) 516
face-to-face interviews 350
FACT see Function Assessment of Cancer Therapy (FACT)
FAMCARE Scale 293, 314
Family Inventory of Needs (FIN) 314
Husbands (FIN-H) 314
family members and friends
HRQOL assessment 288
needs assessment 306
proxy measures of patient-oriented outcomes 348–9
see also caregivers
fatigue 625–30
Feeling Thermometer (FT) 71–3
Ferrans and Powers Quality of Life Index (QLI) 16–17, 21, 23
psychometric data and validation 34–42
quality-of-life dimensions 16
survivorship studies 246, 251
type of information elicited 21
see also Quality of Life Index (QLI)
Ferrans model 17
field testing 301
Fisher’s Theorem 514
final endpoints see endpoints
finasteride 221
FLIC see Functional Living Index Cancer (FLIC)
functioning factors 22–3
Food and Drug Administration (FDA) 550, 552–4
regulatory perspective on HRQOL endpoints 552–4
guidance and standards 555, 556–7, 561
foreign language questionnaires see translation
form, design of 354
Forest plot 375, 377
Fowler Prostate Cancer Outcomes Assessment 250
frame-of-reference effects 618–19
friends see family members and friends
Function Assessment of Cancer Therapy (FACT) 21, 23, 95
breast cancer module (FACT-B) 97, 98, 99–100, 105
representative scores 102
colorectal cancer module (FACT-C) 179–84, 194
construct validity 81
end-of-life studies 276, 277
dendrocline subscale 210
FACTG 251, 276
General (FACT-G) 55, 98
breast cancer studies 97, 98, 99–100
changes in scores 395
colorectal cancer studies 180–4
features 55
Function Assessment of Cancer Therapy (FACT) (cont.)

- performance across the cancer continuum: 55
- prostate cancer studies: 126, 135, 145, 148, 151
- psychometric data and validation: 46–53, 99–100, 135, 418
- translation and cultural adaptation: 416, 417, 419, 420–1
- usage: 55

lung cancer module (FACT-L): 162, 163–5, 171
- construct validity: 165
- content validity: 165
- criterion-related validity: 165
- Trial Outcome Index: 164–5
- profiles: 31
- prostate cancer module (FACT-P): 126, 135, 146, 148
- psychometric properties: 135
- representative scores: 142
- quality-of-life dimensions: 16
- survivorship studies: 246, 251, 255
- type of information elicited: 21

functional assessment: 386, 597–8

Functional Living Index – Cancer (FLIC): 55–6, 95
- breast cancer studies: 96, 97, 165
- representative scores: 103
- colorectal cancer studies: 178, 189
- features: 55–6
- performance across the cancer continuum: 56
- prostate cancer studies: 126, 156–1
- psychometric data and validation: 46–53
- quality-of-life dimensions: 16
- survivorship studies: 247, 251
- translation and cultural adaptation: 407–8, 419
- psychometric performance: 407–8
- usage: 56

functional status: 26
- assessment: 386, 597–8
- measures: 7
- see also health status

Gelu (Good-Bad-Uncertain) Index: 369–70
- gemcitabine: 630
- genetic counseling: 222–4
- performance across the cancer continuum: 223
- genetic testing: 217, 222–4
- breast cancer: 222–3, 224
- negative test result: 222
- ovarian cancer susceptibility: 223
- positive test result: 222–4
- prophylactic surgery and: 224
- subsequent surveillance and: 222–4

short-term outcomes: 217
- literature review: 218
- measurement: 223, 229–31
- see also screening

Gibbs Sampling: 515
- Gnder et al: prostate cancer specific questionnaire: 126, 135, 136
- psychometric properties: 135–7
- global rating measures: 7, 394–6
- relationship to magnitude of HRQOL change: 394–6
- gosomin see hormonal therapy
- graded response model (GRM): 430–2, 448–51
- graphical presentation of data: 375, 376, 377
- grief: 280
- Group Health Cooperative of Puget Sound: 539
- health
- conception of: 614–15
- determinants of: 593–5
- physical versus mental health: 614
- see also health status
- health care policy, influence of patient-reported outcomes: 587–8
- health care utilization: 396
- Health, Eating, Activity, and Lifestyle (HEAL) Study: 532, 536
- Health Insurance Portability and Accountability Act (HIPAA): 543
- health state preference measurement: 8–9, 496–7
- hypothetical health states: 77
- see also disability-adjusted life years (DALYs); preference-based outcome measures; quality-adjusted life years (QALYs)
- health status: 593–5
- marker states: 72
- model: 24
- quality of life relationship: 25, 26, 558
- functional status: 26
- see also functional status; health state preference measurement
- Health Utilities Index (HUI): 80–3
- Mark 1 (HUI): 80
- Mark 2 (HUI2): 79, 80
- Mark 3 (HUI3): 79, 80–1, 82
- measurement properties: 81–3
- construct validity: 81
- content validity: 81
- practical aspects: 83
reliability 82
responsiveness 82–3
strengths and limitations 85
health-related quality of life (HRQOL) 14–15, 27, 584, 625
added value of HRQOL data 555–9, 574–5
prognostic value 559
relationship with clinical status 558
treatment differences 558–9
breast cancer studies 105–6, 107–8, 570
added benefits of HRQOL measurement 111–13
adjuvant drug therapy 106–7, 109, 115
advanced disease treatment 107–8, 109–10
follow-up studies 108, 110
primary breast tumor treatment 106, 107
psychosocial interventions 108, 110–11, 115
survivorship studies 243–4
symptom control 108, 110
see also health-related quality of life (HRQOL) assessment
causal models 23–7
Patrick and Chiang model 25–6
Ware health status model 24
Wilson and Cleary model 24–5, 26
chemoprevention impact 219–22
colorectal cancer studies 571
qualitative findings 190–1
treatment impact 185–90
value added 191–2
see also health-related quality of life (HRQOL) assessment
cultural variation 421
definitions 7, 8, 18–19, 568, 571
as attitudinal versus objective variable 613
categories of 18–19
diversity of 613
issues 591
selection of 19
domains of 15–18, 571–2
impact of cancer therapy 204–5
in instruments for cancer care 18
end-of-life studies 264
domains of HRQOL affected 265–6
importance of HRQOL at end of life 264–5
role in palliative care research 279–80
HRQOL outcomes 389–90
classification based on level of decision making 391
health determinants and 595
primary outcomes 389
relationship among different outcomes 573–5
role in palliative care 278–80
secondary outcomes 389–90
see also patient-reported outcomes (PROs)
HRQOL profile 388–9
impact of cancer therapy 284–5, 218–13, 550
chemotherapy 208–10
radiation therapy 207–8
surgery 207
see also patient perspectives on cancer care
interpretation of HRQOL data 391–8, 399–400, 573
aggregated versus disaggregated scores 392
anchor-based interpretations 393–6
by clinicians 397
by regulatory agencies 397–8
decision significance 573
distribution-based interpretations 392–3
in efficacy, effectiveness or cost-effectiveness studies 398
recommendations 398–9
lung cancer studies 166, 571
survivorship studies 244
value added 166–9
measurement of see health-related quality of life (HRQOL) assessment
mortality relationship 396
needs relationships 308
prostate cancer studies 128–9, 571
survivor’s perspective 286–9
see also health-related quality of life (HRQOL) assessment
regulatory perspective 552–4
survivors see survivorship studies
use of HRQOL information by patients and caregivers 10, 554
by regulatory agencies 11–12, 397–8, 550, 552–4
current situation 586
future directions 559–61
guidance and standards 555, 556–7, 559–60, 581
in clinical decision making 18, 389–90, 554, 581, 588
in drug development 11–12, 550, 551–5, 624
in drug labeling 552, 553–4, 555, 559–60
patient monitoring 390
versus quality of life 14–15
see also quality of life
health-related quality of life (HRQOL) assessment 2–3, 306–8, 387, 399–400
across the cancer continuum 9–10, 570
see also cancer prevention; cancer treatment; end-of-life (EOL) care; screening; survivorship studies
health-related quality of life (HRQOL) assessment (cont.)

breast cancer 9, 94
added benefits of HRQOL measurement 111–13
future research needs 113–16
history of 94–5
in randomized clinical trials 95, 105–11, 114–15, 116
instrument selection 104–5
instruments used 96–7, 101, 105–6
literature review 96
recommendations 113–16
studies using more than one instrument 101–5
see also health-related quality of life (HRQOL)
classification according to purpose of assessment 387–91
clinical decision making 389–90
communication facilitation 390–4
preference (utility) assessment 390
profile description 388–9
screening 388
cognitive interviewing application 612–19
colorectal cancer 9
clinical implications 193–5
future research needs 195
instruments 179–84
measurement issues 184–5
performance of HRQOL measures 192–3
recommendations 195
targeted assessments 195
see also health-related quality of life (HRQOL)
distinction from symptom assessment 387, 552
during treatment 9
colorectal cancer 9
domains of HRQOL affected by cancer therapy 204–5
lung cancer 9
prostate cancer 9
end-of-life studies 10, 264, 276
instruments used 17, 266–73, 276
methodological considerations 277–9
moving away from narrow symptom focus 276–7
role in palliative care research 279–40
families and friends of patients 280
feasibility 569
frame-of-reference effects 618–19
funding issues 113–14
future needs 399
in clinical trials 346, 551–3
assessment after discontinuation of therapy 355–6
data collection modes 348–53
duration of HRQOL assessment 355
frequency of evaluations 355
instrument selection 578
measurement across phases of drug development 348
measurement across stages of disease 346–8
regulatory perspective 552–3
timing of follow-up assessments 356
timing of initial assessment 356
timing when therapy is cyclic 356
instruments 15–16, 17, 27, 31, 32, 406, 570
adaptation of 10–11
balance of error 474
challenges 571–3, 587, 591–2
construct validity 573
test–retest validity 572
core set of measures 579
crosswalking scores between instruments 458–9, 576
evaluation of 453–5, 568–1
future research issues 57–8, 114, 580
general cancer instruments 45–53, 57
generic instruments 32–42, 45
in survivorship studies 245–53
incorporation of patients’ concerns 16–17
item bias 461–2, 463
nonstandard use of 379
positive accomplishments of 367–8
profiles 31
psychometric data and validation 34–42, 46–53, 99–100, 587
quality of 569
redesign of 453–5, 572–3
reliability 573
responsiveness 568–1
selection of 17, 578–9
types of information elicited 21
validity assessment 595
see also instrument construction; item banks; patient-reported outcomes (PROs); specific instruments
lung cancer 9, 170–2
analytic concerns 169–70
curative treatment 166–9
instruments 161–4, 166, 187–8
non-randomized studies 169
randomized studies 169
see also health-related quality of life (HRQOL)
measurement approaches 11
item response theory modeling 11
multidimensional approach 11, 456, 465, 576–7
see also item response theory (IRT)
measures 8–9, 25
cancer-specific measures 8
functional status measures 7
general cancer measures 7, 8, 45–53, 57
generic measures 7, 32–42, 45
global rating measures 7
symptom measures 7
see also patient-reported outcomes (PROs)
methodological issues 114
new directions 575–8
objective assessment 19
prostate cancer 9, 130–1
added value of HRQOL assessments 147–8, 288
future research needs 152–3
instruments used 126, 131–47, 148, 150–2, 288
ongoing assessment 288
performance of HRQOL measures 148–52
see also health-related quality of life (HRQOL)
proxy measures of patient-oriented outcomes 349
qualitative approaches 254–5
recommendations 398–9
statistical issues 386–8
subjective assessment 19–23
evaluations 19–22, 23, 27
perceived status 19–21, 22, 27
unanticipated findings 17–18
see also cognitive interviewing technique; health-related quality of life (HRQOL); patient-reported outcomes (PROs); quality of life
Healthcare Cost and Utilization Project (HCUP) 534, 537
HMO Cancer Research Network (CBS) 541
Hodgkin’s disease 17–18
Home Care Study
caretaker form (HCS-CF) 315
patient form (HCS-PF) 311
Home Caregiver Need Survey (HCNS) 314
hospital therapy
breast cancer 202–3, 210
HRQOL studies 109
impact on patients 205
measurement 210
prostate cancer 127–8, 203
survivorship studies 245
Hospital Anxiety and Depression Scale (HADS) 32–3
breast cancer studies 97, 98, 105
colorectal cancer studies 179, 189
features 32–3
lung cancer studies 161
performance across the cancer continuum 33
prostate cancer studies 126, 134–45
psychometric data and validation 34–42
survivorship studies 249
usage 33, 45
hospitalization costs 485
household costs induced by cancer 492–4
economic evaluations 494
patient-level burden 483–4
population-level burden 492–3
human papilloma virus (HPV) 221–2
hybrid conjoint model 324, 325
Impact of Event Scale (IES) 248, 252
Index of Coexistent Disease (ICED) 151
Indian Health Service, Resource and Patient Management System 539
informal caregivers see caregivers
information 598
Support Needs Questionnaire (SNQ) 315
instrument construction 453–5, 477, 575–6
discovery methods 591–2
Four Building Blocks 466–72, 477
construct map 466–8
items design 468
measurement model 469–72
outcome space 468–9
see also specific instruments
Instrumental Activities of Daily Living (IADL) survivorship studies 249
insurance claims data 528–4
see also administrative data
Integrated Delivery System Research Network (IDSRN) 543
intent-to-treat (ITT) analysis 372–4
interaction analysis 281–2
International Breast Cancer Study Group (IBCSG) 101
International Index of Erectile Function (IIEF) 126, 146–7
International Prostate Symptom Score (IPSS) 126, 147
survivorship studies 250
international studies 406
see also cross-cultural use of HRQOL assessments
interpersonal care 291
patient perspectives 291–2
evaluations 291–2
reports 291–2
see also communication issues
interviews
to-face-to-face 350
telephone 350
Inventory of Complicated Grief (ICG): 315
item aggregation: 476
item banks: 439, 445, 455, 592
adding items: 456–8
development of: 455–6, 576, 580, 601
item bias: 461–2, 463, 596
item difficulty: 596–8
item discrimination: 598–9
item information function (IIF): 436–7, 453
item response theory (IRT) modeling: 11, 425–7, 445, 561, 575, 591
applicability: 379
applications: 425, 445, 446, 462–3, 561
crosswalking scores between instruments: 458–9, 576
detecting potentially biased test items: 461–2, 463
instrument construction and evaluation: 453–5, 572–3, 575–6
item bank development: 455–8, 576
model selection and: 600
optimal scaling/scale score interpretation: 440–1
reducing patient burden: 369
scale development and analysis: 438–9
summary scores: 577
see also differential item functioning (DIF)
assumptions: 432–3, 446–53
assessment of: 446–53
local independence: 433
model fit: 448–53
monotonicity: 432
unidimensionality: 432–3, 446–8, 465
basics: 427–32
dichotomous response data: 428–30
polytomous response data: 430–2
category response curves (CRCs): 431, 448–51
comparison with classic test theory (CTT) approach: 434–8, 575–6, 591
estimation of item and person parameters: 433–4
item-fit: 434
person-fit: 434
evaluation of fit: 434
extensions to: 620
future role in outcomes assessment: 441–2
information concept: 436–8
applications: 438–41
item information function (IIF): 436–7, 453
scale information function (SIF): 437–8, 453–5
target information function: 453
trait score estimation: 454–5
invariance property: 435–6
applications: 438–41
item characteristic curve (ICC): 598
item response curve (IRC): 427–8, 434
model selection: 599–600
multidimensional approach: 11, 456, 465, 576–7
see also multidimensional item response modeling (MIRM)
obstacles to greater use: 426
standardized residuals (SRs): 451–3
terminology: 427
items design: 460
Japanese Quality of Life Research Group: 209
Kaiser Permanente: 539
 Karnofsky Performance Status Scale (KPS): 386
labeling: see drug labeling
Late Effects of Normal Tissues/Subjective-Objective Management Analytic (LENT/SOMA) scales: 206
Late Morbidity Scoring Criteria: 206
levels of evidence: 386
linear analogue self-assessment (LASA) scales: 206
breast cancer: 101
Lipscomb, Joseph: 4
list prices: 488
local independence: 433
long-term care costs: 491–2
Long-Term Quality of Life (LTLQ): 254
survivorship studies: 247, 253–255
longitudinal analysis: 301, 374–5
lost productivity costs: 492–4
economic evaluations: 494
patient-level burden of cancer: 493–4
population-level burden of cancer: 492–3
lung cancer: 5
HRQOL studies: 170–2, 571
analytic concerns: 109–10
curative treatment: 166–9
findings: 166
instruments used: 161–4, 166, 167–8
literature search: 160–1
non-randomized studies: 169
randomized studies: 169
value added: 166–9

© Cambridge University Press www.cambridge.org
Cambridge University Press
0521838908 - Outcomes Assessment in Cancer: Measures, Methods, and Applications
Edited by Joseph Lipscomb, Carolyn C. Gotay and Claire Snyder
More information

652 Index
mortality 168
non-small-cell (NSCLC) 160, 203
small-cell (SCLC) 160, 203
survivorship studies 244
instruments used 245–53
treatments 160, 203
cost-effectiveness analysis 504
curative treatment 166–9
decision-making 160
HRQOL studies 9, 166–9
impact on patients 205
see also cancer treatments
Lung Cancer Symptom Scale (LCSS) 162, 163–4, 165–6, 171
construct validity 165
content validity 165
criterion-related validity 165–6
reliability 165
M-Plus program 477
McGill Quality of Life Questionnaire (MQOL) 15–16, 274–5
end-of-life studies 269–71, 274–5, 277
quality of life dimensions 16
mammography see breast cancer
Mammography Questionnaire 294
marker states 72
Markov State-Transition models 567–8, 510
Massachusetts Male Aging Study 146–7
mastectomy 202–3
HRQOL studies 106
impact on patients 204, 205
treatment decisions 93
Medicaid 588
claims files 527
see also administrative data
Medical Care Attitude Scale (MCAS) 294
medical care costs 482–91
economic evaluations 490–1
patient-level burden of cancer 485–90
population-level burden of cancer 483–5
Medical Expenditure Panel Survey (MEPS) 514, 537, 539
Medical Outcomes Studies Short Form Health Survey see Short Form 36 (SF-36)
Medicare 588
claims data 526–7
see also administrative data
Cost Reports (MCRs) 489
Current Beneficiary Survey (MCBS) 535, 537–8, 539
Health Outcomes Survey (HOS) 538, 532
Memorial Symptom Assessment Scale (MSAS) 271–3, 275, 277
Global Distress Index (GDI) 275
Mental Adjustment to Cancer (MAC) Scale 248, 252
microcosting 481, 485
assigning costs to specific procedures and services 488
attributable cost measurement 486, 487
long-term care costs 492
minimum important difference (MID) 394
mirror image stream plot 375, 376
missing data 353–5, 372, 373, 561, 631
analysis approaches 356–8, 371–2, 561, 631
avoidance of 353–4, 569
education and training 354
form design 354
primary prevention 353–4
secondary prevention 354
colorectal cancer studies 191–2
data collection and management 353
follow-up procedures 354–5
lung cancer studies 169–70, 171
Missoula-VITAS Quality of Life Index (MVQOLI) 268–9, 274, 277
mitomycin 630
Montreal Prostate Cancer Model 511
multi-attribute preference-based measures see preference-based outcome measures
Multitrait Health Status (MTHS) 190
multidimensional approach 11, 436, 465, 576–7
multidimensional item response modeling (MIBM) 465, 474–6, 477
aggregate score derivation 476–7, 577
item aggregation 476
subscale aggregation 476–7
comparison with multidimensional approaches 466
future research and applications 477–8
software options 477
multidimensional random coefficients multinomial logit (MRCML) model 475
multinational studies 406
see also cross-cultural use of HRQOL assessments

© Cambridge University Press www.cambridge.org
Cambridge University Press 0521838908 - Outcomes Assessment in Cancer: Measures, Methods, and Applications
Edited by Joseph Lipscomb, Carolyn C. Gotay and Claire Snyder
Index
More information

© Cambridge University Press www.cambridge.org
Cambridge University Press 0521838908 - Outcomes Assessment in Cancer: Measures, Methods, and Applications
Edited by Joseph Lipscomb, Carolyn C. Gotay and Claire Snyder
Index
More information
multiple endpoints 356–7, 378–1
Multiple Outcomes of Raloxifene Evaluation (MORE) Trial 229
National Cancer Data Base (NCDB) 524, 525
strengths and limitations 525
national cancer data system 544–6
National Cancer Institute (NCI) 3
Assessment of Patients’ Experience of Cancer Care (APECC) Study 533, 536
Breast Cancer Surveillance Consortium 536
Clinical Trials Cooperative Group 541–2
Community Clinical Oncology Programs (CCOPs) 541–2
Comprehensive Cancer Centers (CCC) 543
Health, Eating, Activity, and Lifestyle (HEAL) Study 532, 536
Physician Survey of Cancer Susceptibility Testing 533, 536
Survey of Colorectal Cancer Screening Practices 533, 536
toxicity criteria 206
see also Cancer Outcomes Measurement Working Group (COMWG)
National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) 206
National Center for Health Statistics (NCHS)
National Ambulatory Medical Care Survey (NAMCS) 534, 537
National Hospital Discharge Survey (NHDS) 534, 537
National Comprehensive Cancer Network (NCCN) 541
National Health and Nutrition Examination Survey 530, 531
national health care policy see health care policy
National Health Interview Survey (NHIS) 536, 531, 590
National Hospital Discharge Survey (NHDS) 534, 537
National Initiative on Cancer Care Quality (NICCQ) 540–1
National Institute for Clinical Excellence (NICE), UK 588
National Long-Term Care Survey 536
National Program of Cancer Registries (NPCR) 524
strengths and limitations 525
National Survey of Colorectal Cancer Screening Practices 533, 536
National Survey of Mammography Facilities 536
nurses assessment 19
Need Evaluation Questionnaire (NEQ) 311
needs 305, 310, 320–2
hierarchy of 305
identification of 318–19, 524–5
critical incident technique 318
person-focused techniques 318–19
importance of influencing factors 319–22
measurement 322–4
trade-offs 322
of caregivers 310, 320–2
relationships among needs 308, 325
relationships with satisfaction and HRQOL 388, 325
needs assessment 10, 306–8, 573–4
developing and conducting a needs assessment 317–24
factors influencing the importance of needs 319–22
measuring importance of needs 322–4
needs identification 318–19, 324–5
distinction from satisfaction and HRQOL assessment 306–8
family members 306
importance of 305–6
instruments review 308–15, 317
domains 309–17
instrument characteristics 309
literature search 306–9
recommendations 324–5
Needs Near the End-of-Life Care Screening Tool (NEST) 313
net benefit analysis 514–15
net monetary benefit (NMB) 514–15
Regrssion methods 515–16
non-steroidal anti-inflammatory agents (NSAIDs) 221
Nottingham Health Profile (NHP) 34–42
colorectal cancer studies 179, 185
survivorship studies 248
nursing home care costs 490
objective assessment 18
On-Line Guide to Quality-of-Life Assessment (OLGA) 32
Oncology Treatment Toxicity Assessment Tool (OTAT) 267
1-parameter logistic model (1PLM) 429–30
optical scanning 351
outcome space 468–9
outcomes measurement 2–4, 590–1
desirable characteristics of outcome measures 3
identification of 7
Fine D’s 590
new directions 575–8, 580–2
sustaining scientific advancement 590–1
outcomes assessment framework 4–6
arenas of application 5
continuum of care 5, 570
disease focus 5
outcome measures of prime interest 4–5
proxy measures of patient-oriented outcomes 348–9
see also health-related quality of life (HRQOL) assessment;
patient-reported outcomes (PROs); preference-based outcome measures

© Cambridge University Press www.cambridge.org
Cambridge University Press
0521838908 - Outcomes Assessment in Cancer: Measures, Methods, and Applications
Edited by Joseph Lipscomb, Carolyn C. Gotay and Claire Snyder
More information
outcomes research 1–2, 522
common clinical outcomes 386
current situation 586
endpoints 1–2, 386
construction and validation of 379
end-of-life care 276–7
identification and measurement of 367–8
multiple endpoints 556–7, 370–1
future research needs 445, 580–2
data source enhancement 581
role of outcome measures in decision making 581
sustaining scientific advancement 580–1
HRQOL outcomes 389–90
primary outcomes 389
secondary outcomes 389–90
see also health-related quality of life (HRQOL) assessment
influence on health care policy 587–8
literature review 3, 6–7, 364
methodological challenges 10–11, 587
analytical techniques 10
study guidelines 587
psychometric theory in 11
statistical issues see statistical analyses in outcomes research
see also data sources, outcomes measurement
ovarian cancer susceptibility testing 223
paid amounts 489
pain
assessment in prostate cancer palliative treatments 147
management of 265
quality-of-life relationship 585
palliative care 264
lung cancer 170–1
prostate cancer 147
role for HRQOL outcomes 279–80
see also end-of-life (EOL) care
Palliative Care Assessment (PACA) 313
pancreatic cancer economic burden 485
Pap smear test 2 cervical cancer
Paradigm of Cancer Survivorship 255
patient education 298–9
patient expectations 297–8
influence on patient evaluations 297–8, 299
Patient Information Need Questionnaire (PINQ) 312, 316
Patient Needs Assessment Tool (PNAT) 312, 316
patient perspectives on cancer care 10, 290–1, 623–4
challenges with patient evaluation measures 297–9
influence of expectations 297–8, 299
influence of patient characteristics 298–9
predispositions 298
evaluations versus reports 291–2, 299
instrument review 292–5, 297
cancer specific versus general measures 296–7
continuum of care and cancer site 297
cultural and language differences 296
domains 295
reference period 296
reliability and validity 296
respondents 296
response options 296
sensitivity of measures 296
weighting the importance of domains 295–6
interpersonal care 291–2
literature search 292
measurement of 292
questionnaire development 300–1
cognitive testing 301
domain development and refinement 300–1
field testing 301
longitudinal research 301
new item construction 301
ratings 291
recommended strategy 300–1
questionnaire content 300
reports 291–2
potential usefulness of 299–300
satisfaction 291
needs relationships 308
technical care 291
value of 623–4
see also patient-reported outcomes (PROs)
patient satisfaction see patient perspectives on cancer care;
satisfaction surveys
patient satisfaction with medical care (PSMC) item bank 456
development of 456–8
Patient Satisfaction with Medical Care Questionnaire (PSMQ-III) 446, 447, 449, 456–7, 460
principal components analysis 448
scale information function 453–5
patient well-being see well-being
patient-oriented prostate utility scale (PORPUS) 84–5
patient-reported outcomes (PROs) 530–6, 584, 623, 624–31
clinically important effects 631–2
current usage of 586
data collection modes 348–53
cost considerations 351
face-to-face interview 350
patient-reported outcomes (PROs) (cont.)
  mailed self-assessment 351
  proxy measures from caregivers/family 348–9
  self-administration versus interviewer
  administration 349–50
  telephone interview 350

  definitional considerations 624–5
  drug advertising and promotion and 630–1
  history of research 584–6
  in clinical trials 346–7, 551–3, 587, 624
  assessment after discontinuation of therapy 355–6
  duration of HRQOL assessment 355
  frequency of evaluations 355
  measurement across phases of drug development 348
  measurement across stages of disease 346–8
  multiple testing 631
  recommendations 358–9
  regulatory perspective 552–3
  timing of assessments when therapy is cyclic 356
  timing of follow-up assessments 356
  timing of initial assessment 356
  in medical records 529

  influences on 587
  media for data collection 351–2
  computer-assisted self-interview (CASI) 352
  cost considerations 352
  hand-held computers (PDAs) 352
  optical scanning 351
  pencil and paper 351
  missing data 353–5, 631
  analysis approaches 356–8, 371–2, 631
  avoidance of 353–4
  data collection and management 353
  follow-up procedures 354–5
  HRQOL 7, 16–17, 21, 69
  prostate cancer 149–50
  treatment-related toxicity 169, 207
  product labeling and 625–9, 630
  significance for health care policy 587–8
  statistical considerations 621–3
  Bayesian approaches 632–3
  study quality 352–3
  value added 107–8
  see also health-related quality of life (HRQOL); patient
  perspectives on cancer care; subjective
  assessment

  patients see cancer patients
  PCOS Prostate Index 250

  perceived status 19–21, 27
  in definitions of quality of life 20–2
  measurement of 22
  Physician Trade-Off (PTO) technique 498
  personal data assistants (PDAs), for patient-reported data
  collection 352
  pharmaceutical industry vs drug development
  Physician Estimate of Survival 33
  Physician Survey of Cancer Susceptibility Testing 513, 536
  Picker Survey 295, 300
  Policy Analysis Institute Questionnaire 249
  policy issues see/health care policy
  POLYFIT program 451–2
  Post-Traumatic Stress Disorder (PTSD) Checklist 249
  preference-based outcome measures 69–71, 87
  direct 69, 71–8, 86
  hypothetical health states 77
  standard gamble (SG) 73, 74, 75–7
  strengths and limitations 85
  surrogate informants 77
  time trade-off (TTO) 74, 75–7
  visual analogue scale (VAS) 71–3
  employment of in cancer intervention studies 70–1
  implications for research agenda 85–7
  computer-assisted preference elicitation 86–7
  direct versus multi-attribute measures 86
  future directions 87
  importance of choice-based preference elicitation 86
  preference-based measures as complement to other
  approaches 86
  indirect (multi-attribute approach) 69–70, 78–85, 86
  disease-specific multi-attribute systems 84–5
  EuroQol EQ-5D 78–80
  Health Utilities Index (HUI) 80–3
  Quality of Well-Being Scale (QWB) 83–4
  selection of multi-attribute system 84
  strengths and limitations 85
  see also outcomes measurement; patient-reported outcomes
  (PROs)
  prevention see/cancer prevention
  prices, versus costs 588–9
  Primary Care Practice-Based Research Networks (PCPRNs) 543
  Princess Margaret Hospital Patients Satisfaction with Doctor
  Questionnaire 293
  principal components analysis (PCA) 446, 448
  privacy regulations 545
  probabilistic sensitivity analysis 513–14
  probability (P) value 393
Index 657

Prostate Cancer Intervention Versus Observation (PIVOT) trial 148
Prostate Cancer Needs Assessment (PCNA) 312
Prostate Cancer Prevention Trial (PCPT) 126, 149, 219, 221
Prostate Cancer Specific Quality of Life Instrument (PROSEQOL) 126, 135
psychometric properties 135
Prostate Cancer Treatment Outcome Questionnaire 250
Prostate, Lung, Colon and Ovary Trial (PLCO) 127
prostate-specific antigen (PSA) screening 126
Psychological Adjustment to Illness Scale (PAIS) survivorship studies 247, 253
psychological impacts breast cancer 94–5 end-of-life studies 266
cancer caregivers 331–3 prostate cancer 134–45
survivor's perspective 287–8
late effects of cancer treatment 244
survivorship studies 249, 253
psychometric equivalence 595
psychosocial interventions, breast cancer 108, 110–11, 115
qualitative approaches 254–5 colorectal cancer studies 190–1
cancer end-of-life studies 279
survivorship studies 250, 254–5
quality of care 3
categories of 291
cancer caregiver perspectives 290–2
evaluations 291–2
instrument review 292–7
reports 291–2
quality of life 14, 15, 625
definitions 19–21, 22, 591
health status relationship 25, 26, 550
functional status 26
versus health-related quality of life 14–15
see also health-related quality of life (HRQOL), well-being
Quality of Life and Well-being Questionnaire 179
Quality of Life-Cancer Survivors (QOL-CS) 247, 252, 254
Quality of Life Index (QLI) 43–4
features 43–4
performance across the cancer continuum 44
prostate cancer studies 126
psychometric data and validation 34–42

problem-oriented medical record (POMR) 486–7
production costs 489–90
Profile of Mood States (POMS) 43
alternative language studies 417
breast cancer studies 97, 98–101, 105
colorectal cancer studies 179
features 43
performance across the cancer continuum 43
prostate cancer studies 126, 134–45, 150–1
psychometric data and validation 34–42
survivorship studies 248, 252–3
usage 43
prophylactic surgery 224
prostate cancer 5
chemoprevention 126, 221
short-term outcome measurement 219
continuum of care 126–8
economic burden of 465
end-of-life care 128
HRQOL studies 128–9, 571
added value of HRQOL assessments 147–8
during treatment 9
future research needs 152–3
instruments used 126, 131–47, 148, 150–2, 288
literature search 129
measurement of HRQOL 130–1
multi-attribute preference systems 84–5
ongoing assessment 288
performance of HRQOL measures 148–52
need for 287–8
screening 126–7, 228
short-term outcomes measurement 225–7
survivorship studies 229
survivor's perspective 256–8
diagnosis 286–7
long-term survivorship 287–8
potential contributions of HRQOL assessment 288
recommendations 288–9
treatment 287
survivorship studies 128, 244–5
instruments used 245–53
treatments 127–8, 203
HRQOL endpoints 147–8
impact on patients 9, 131, 156, 205
quality of life measures 129
treatment decisions 147, 148–50, 558
treatment preferences 288
see also cancer treatments
Prostate Cancer Index 21

© Cambridge University Press www.cambridge.org

Cambridge University Press
0521838908 - Outcomes Assessment in Cancer: Measures, Methods, and Applications
Edited by Joseph Lipscomb, Carolyn C. Gotay and Claire Snyder

More information
Quality of Life Index (QLI) (cont.)
- quality-of-life dimensions 16
- usage 44
  see also Ferrans and Powers Quality of Life Index

Quality of Life Inventory 23

Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-AC20) 209–10

Quality of Life Questionnaire-C30 see EORTC QLQ-C30

Quality of Life Scale for Cancer (QOL-CA) 16–17
- quality-of-life dimensions 16
- type of information elicited 21

Quality of Well-Being Scale (QWB) 79, 207–8, 209
- measurement properties 83–4
- content validity 83
- practical aspects 84
- reliability 83–4
- responsiveness 81

quality-adjusted life years (QALYs) 70, 504–5
- cancer burden measurement 485, 496–7
- equity issues 498

quality-adjusted time without symptoms or toxicity (Q-TWIST) 78

radiation therapy
- breast cancer 93, 202–3
- cost-utility analysis 505
- HRQOL studies 106
- treatment decisions 93
- colorectal cancer 178, 203
- impact on cancer patients 201–2
domains of HRQOL affected 204–5
measurement 207–8
patient-reported instruments 207
toxicity criteria 206–7
- lung cancer 203
- prostate cancer 203
- survivorship studies 245
- see also cancer treatments

Radiation Therapy Oncology Group (RTOG) toxicity criteria 206
- radionuclide 220–1
- RAND Mental Health Index 150–1
- randomized clinical trials 206
- randomized cost-effectiveness trials see cost-effectiveness analysis (CEA)

Rasch model 17, 206–7, 438, 470, 508–9
- model selection 509–600
- recall bias 395
- rectal cancer treatment 178
  see also colorectal cancer
- reference periods 296, 616–17
- probing the past 617
- probing the present 616
- reframing 188
- regulatory agencies
  interpretation of HRQOL data 397–8
  use of HRQOL data 11–12, 550
- guidance and standards 355, 506–7, 559–60, 581
- regulatory perspective on HRQOL endpoints 552–4
- Research Association of Practicing Physicians (RAPP) 543
- Resource-Based Relative Value Scale (RBRVS) 490
- response shift 378–9, 385, 573, 618–19
- retrospective computerized episode algorithms 488
- retrospective episode coding 487–8
- revenues 489
- Revised Grief Experience Inventory (RGEI) 315
- Rotterdam Symptom Checklist (RSCL) 56–7
- breast cancer studies 96, 97, 105
colorectal cancer studies 179, 189
- features 56
- lung cancer studies 161
- performance across the cancer continuum 56–7
- prostate cancer studies 128
- psychometric data and validation 46–53
- survivorship studies 249
- translation and cultural adaptation 409–10, 419
- psychometric performance 410–11

usage 56–7
RSCL see Rotterdam Symptom Checklist (RSCL)
sample attrition 371–2
- satisfaction surveys 293, 306–8, 590
- use in needs assessment 322
- see also patient perspectives on cancer care

scale information function (SIF) 437–8, 453–5
- scales development and analysis 438–9
- optimal scaling/scale score interpretation 440–1
- screening 210, 217, 224–9
- breast cancer 225–7, 228–9
- false positive screening results 228–9
- negative screening results 228
cervical cancer 225–7, 228–9
false positive screening results 228
negative screening results 228
colorectal cancer 178, 224–7, 228, 536
cost-effectiveness analysis 512
decision making 217
HRQOL status 388
HRQOL studies 9
negative test result 217–18, 228
false negative 217–18
positive test result 217, 218
false positive 217, 228–9
prostate cancer 126, 225–7, 228
short-term outcomes 217, 218, 231–2
literature review 218
measurement of 225–7, 229–31
measures 218
see also genetic testing
selection bias 375
selective estrogen receptor modulators (SERMs) 220
see also raloxifene; tamoxifen
Selenium and Vitamin E Cancer Prevention Trial (SELECT) 221
self-explicated utility model 324
hybrid conjoint model 324, 325
sensitivity analysis 513–14
sexual dysfunction
measurement 146–7
prostate cancer treatment and 131, 150
survivorship studies 245
Short Form 6D (SF-6D) 87
Short Form 36 (SF-36) 21, 31, 33–43, 465–6, 472–6
breast cancer studies 97, 98, 105
representative scores 103
features 33
item response theory (IRT) modeling 426–7, 430–2
dimensionality 432–3
scale information function 437
standard error of measurement function 438
multidimensional item response modeling (MDRM) approach 474–6, 477
Omnibus Summary Scale 476
performance across the cancer continuum 33–43
Physical Functioning (PF-10) subscale
construct map 467–8
construct validity 470–2
items design 469
outcome space 469
prostate cancer studies 128, 134, 150–1
representative scores 140
psychometric data and validation 34–42
quality of life dimensions 16
reliability coefficients 473
subscales perspective 473–4, 477
summary scale perspective 473–4, 477
survivorship studies 245–50, 255
type of information elicited 21
usage 33–43, 45
short-term outcomes 217
measurement of 219, 223, 225–7, 229–31
see also cancer prevention; genetic testing; screening
Sickness Impact Profile (SIP) 31, 44–5, 179
colorectal cancer studies 189–90
features 44
performance across the cancer continuum 44–5
psychometric data and validation 34–42
Short Form (SF-SIP) 44
usage 44–5
skilled nursing facilities (SNF) costs 490
slope parameter 470
Snyder, Claire 4
social impacts
end-of-life care 266
on caregivers 333
social well-being 266
societal costs 495–6
societal value 481
total societal value-loss 496–8
soft-tissue sarcoma 346–8
Southwest Oncology Group Quality of Life Questionnaire 190
Specific Disease and Continence-Related Symptoms questionnaire 179
specific objectivity 430
spiritual domain 266, 587
caregivers 333–4
end-of-life care and 266
Spitzer Quality of Life (QL-Index) colorectal cancer studies 179, 189
quality-of-life dimensions 16
survivorship studies 249
standard deviation (SD) 393
standard error of measurement (SEM) 393, 436, 438
standard gamble (SG) 73, 74, 75–7
measurement properties 75–7
construct validity 72, 75–6
content validity 75
practical aspects 73, 77
standard gamble (SG) (cont.)  
reliability 76  
responsiveness 76  
standardized residuals (SRs) 451–3  
statistical analyses in outcomes research 10, 362–4, 365, 380–1, 569–70  
aggregated versus disaggregated scores 392  
anchor-based interpretations 393–6  
ability to work 396  
global ratings 394–6  
health care utilization 396  
mortality 396  
relationship to disease status and treatment 396  
challenges: 363–5, 366  
distribution-based interpretations 392–3  
future research needs 363–5, 366–7  
Bayes methodology role 379–80, 561, 577–8  
clinical significance assessment 379, 560–1  
endpoint construction and validation 379  
item response theory applicability 379  
nonstandard use of instruments 379  
response shift 378–9  
training needs 379  
gold standard 365–6, 367  
issues 367–8  
clinical response benefit 368, 379  
clinical significance 370, 631–2  
graphical presentation of results: 375, 376, 377  
HRQOL assessment 368–9  
identifying and measuring endpoints 367–8  
intent-to-treat (ITT) analysis 372–4  
longitudinal analysis 374–5  
missing data and sample attrition 371–2, 373  
multiple endpoints 370–1  
role of complex statistical methods 375–8  
selection bias 375  
stratification 369–70  
patient-reported outcomes 631–3  
see also item response theory (IRT)  
stratification 369–70  
structural equation modeling (SEM) 572  
Study of Cancer Survivors-II (SDS-II) 532, 536  
subjective assessment 19–23  
evaluations 19–23, 27  
changes over time 23  
in definitions of quality of life 20–2  
influencing factors 22–3  
measurement of 22  
perceived status 19–21, 27  
in definitions of quality of life 20–2  
measurement of 22  
subjective significance 394–5  
Subjective Significance Questionnaire (SSQ) 394–5  
subscales 465, 466  
aggregation 476–7  
Four Building Blocks 466–7, 477  
construct map 466–8  
items design 469  
measurement model 469–72  
outcome space 468–9  
multidimensional item response model approach 474–6  
reliability 473, 475, 477  
validity 466, 475  
see also specific instruments  
summary scales and scores 465, 466, 577, 582–3  
see also aggregated scales  
support groups, prostate cancer 289  
ned for 287–8  
Support Team Assessment Schedule (STAS) 313  
Supportive Care Needs Survey (SCNS) 311, 316  
measuring importance of needs 322  
surgical treatment  
breast cancer 93, 202–3  
treatment decisions 93, 115–16  
colorectal cancer 178, 203  
clinical implications of HRQOL studies 193, 194  
impact on HRQOL 185–8, 192  
impact on cancer patients 201–2  
domains of HRQOL affected 204–5  
measurement 207  
toxicity criteria 206–7  
lung cancer 203  
prophylactic surgery 224  
prostate cancer 150, 203  
survivorship studies 245  
see also cancer treatments  
Surveillance, Epidemiology, and End Results (SEER)  
program 485, 525–4  
combined SEER/administrative data 526–8, 529  
strengths and limitations 525  
surveys 530–3, 539  
enhancements to support outcomes research 539  
health knowledge, practices, and outcomes 530–6  
resource use and cost 534–5, 536–8  
strengths and limitations 538
survival curves 33
survivorship studies 241–2, 243
breast cancer 243–4
colorectal cancer 245
data abstraction techniques 242
HRQOL assessment 9–10, 241–2, 243–5
adding value 253
future research needs 255–6
instruments used HRQOL 245–53
positive outcomes 242
qualitative approaches 253, 254–5
late effects of cancer treatment 244
literature search 242
lung cancer 244
Paradox of Cancer Survivorship 255
prostate cancer 128, 244–5
survivor’s perspective 286–9
SWOG Prostate Outcomes Questionnaire 250
Symptom Checklist 179
symptoms 264–5
control of 265
breast cancer 110
end-of-life care 279–80
impact on HRQOL 265
measures of 7
distinction from HRQOL assessment 387, 552
T scores 101
tamoxifen
breast cancer chemoprevention 220
HRQOL impact 220–1
see also hormonal therapy
target information function 453
taxanes, cost-effectiveness 563
technical care 291
patient perspectives 291
technique interviews 350
terminally ill patients see end-of-life (EOL) care
test characteristic function (TCF) 458, 459
Therapy-Related Symptom Checklist (TRSC) 207, 208
think-aloud responses 631
see also cognitive interviewing technique
TIME (Toolkit of Instruments to Measure End of life care) 266
time trade-off (TTO) 74, 75–7
measurement properties 75–7
construct validity 72, 75–6
content validity 75
practical aspects 73, 77
reliability 76
responsiveness 76
Toronto Informational Needs Questionnaire—Breast Cancer (TINQ-BC) 313
Total Mood Disturbance (TMD) score 98
toxicity data 386
patient-reported measures 169, 207
toxicity criteria 206–7, 212
training
missing data avoidance 354
statisticians 379
trait scores
computerized adaptive assessment 459–61
estimation of 454–5
statistically equating scores 458–9
translation
Cancer Rehabilitation Evaluation System (CARES) 408–9, 419, 420
psychometric performance 409
Short Form (CARES-SF) 408–9
EORTC QLQ-C30 411–12, 419, 420–1
psychometric performance 412–13, 416
Functional Assessment of Cancer Therapy-General (FACT-G) 416, 419, 420–1
psychometric performance 416–18
Functional Living Index Cancer (FLIC) 416, 419, 420–1
psychometric performance 410–11
Rotterdam Symptom Checklist (RSCL) 409–10, 419
psychometric performance 410–11
recommendations 418–21
Rotterdam Symptom Checklist (RSC) 408–9, 416
survivorship studies 245
screening 250
sensitivity
TOMOS 386
unidimensionality 432–3, 446–8, 465, 592, 593
urinary function
measurement 147
prostate cancer treatment and 131, 150
survivorship studies 245

© Cambridge University Press
www.cambridge.org
utilities 231
 expected utility theory 73
 measurement of 231, 390
 utility scores 71, 390
 see also Health Utilities Index (HUI)

 value scores 71
 verbal probing 611
 see also cognitive interviewing technique
 Veterans Affairs Information Resource Center (VIReC) 539
 video-CASI (computer-assisted self-interview) 352
 visual analogue scale (VAS) 71–3
 measurement properties 72–3
 construct validity 72
 content validity 72
 practical aspects 73
 reliability 72–3
 responsiveness 73
 vomiting assessment 19
 von Neumann–Morgenstern expected utility theory 73

 well-being 585
 physical 266
 psychological 266
 social 266
 spiritual 266
 see also quality of life
 willingness-to-accept (WTA) approach 498
 willingness-to-pay (WTP) approach 497–8, 565–6
 equity issues 498–9
 withholds 488
 working group 4
 see also Cancer Outcomes Measurement Working Group
 (COMWG)
 World Health Organization Quality of Life Questionnaire
 (WHOQOL-BREF) 417
 Worthington Chemotherapy Satisfaction Questionnaire
 (WCSQ) 210, 293–4
 Wright map 470–2, 477

 Zarit Burden Interview/Inventory 340